Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer Treatment

Early Treatment with Lorlatinib Helps in Improving Lung Cancer Survival Rate

Posted on November 23, 2020
Post Views: 533

Lung Cancer TreatmentNon-small cell lung cancer accounts for 87% of all lung cancer cases and some 5% of NSCLC cases are ALK-positive. This implies that they have genetic abnormality in the anaplastic lymphoma kinase gene.

According to the new study led by researchers at Massachusetts General Hospital (MGH) published in the New England Journal of Medicine, lung cancer patients with specific genetic alteration lived longer when treated early with drug Lorlatinib. First and second generation ALK inhibitors have been in development since 2008 and Lorlatinib is a third-generation ALK-inhibitor that has been approved for ALK-positive patients where cancer has progressed after taking older-generation inhibitors. Based on the interim analysis, the study authors have concluded that ALK-positive NSCLC patients who received Loratinib experienced significantly longer PFS and had intracranial responses more often when compared to patients in the crizotinib group.

Lorlatinib is a third-generation inhibitor of anaplastic lymphoma kinase (ALK) and has anti-tumor activity in previously treated patients with ALK positive non-small cell lung cancer. Lorlatinib is currently approved for use in patients who have received advanced despite treatment with past generations of ALK inhibitors. The first-generation and second-generations of ALK inhibitors can be very effective but patients are at risk of metastasis too brain.

Benjamin Solomon, MD, Department of Medical Oncology, Peter MacCallum Cancer Centre in Australia,  said, “Biomarker-driven medicines have improved outcomes for people living with ALK-positive non-small cell lung cancer, but innovative therapies are still needed to delay disease progression.”

The trial is still ongoing and has shown promising results so far but the researchers need to continue to follow lung cancer patients to track long-term outcomes like overall survival.

 

The information shared in this blog is for educational purposes only. For any medical issues, contact your healthcare practitioner.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,303)
  • Lung Cancer: Symptoms and Treatment (5,625)
  • What is Non-Small-Cell Lung Cancer? (5,531)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025
  • Understanding The Stage 0 Lung Cancer April 21, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha. Privacy Policy
%d